Oncology

Many patients have learned about the advances in immunotherapy treatments for cancer, but the media may not be portraying all the complexities and potential harms of these agents, according to Debra L. Madden, cancer research advocate and patient representative. Madden mentioned that biomarker research could help determine which patients are most likely to benefit from immuno-oncology.

The first patient has been treated with ruxolitinib (Jakafi), by Incyte Corporation, for steroid-refractory acute graft-versus-host disease, as part of the REACH-1 phase 2 trial. The trial is evaluating ruxolitinib in combination with corticosteroids.

Oncologists must recognize the importance of the patient voice when making treatment decisions so that the treatment plan can be adapted to each patient’s goals and desires, said Carrie Stricker, PhD, RN, AOCN, chief clinical officer and co-founder of Carevive.

The TAPUR clinical trial is rapidly expanding to new sites, but the researchers have not yet collected enough data to analyze and publish the results, according to Pam Mangat, MS, associate director TAPUR study at the American Society of Clinical Oncology.

According to a new study published in PLOS Medicine, genetic analysis of the uterine lavage fluid from pre- and post-menopausal women can provide early evidence of endometrial cancer.

A glimpse at the top 5 articles from The American Journal of Managed Care's® conference coverage that caught reader attention in 2016.

Twenty-three of 48 states in the United States saw a drop in melanoma—associated death in 2013 compared with 2003, while 21 states witnessed a rise in the death rate.

Cancer care and its associated costs can combine with everyday bills to create a significant financial burden, especially for young adults with cancer, said Samantha Watson, founder and CEO of The Samfund.

A new clinical study to reduce the unwanted side effects of radiation in patients with human papillomavirus (HPV)—positive oropharynx cancers has found that reducing the dose of radiation can maintain the cure rates but avoid some of the late treatment-associated toxicities.

As 2016 draws to a close, here’s a look at the top 5 news articles that captured reader interest on AJMC.com.

Oncology care is often spread out across multiple facilities and providers, so health IT innovators use software to integrate data from these many locations and deliver it to the point of care, according to Jonathan Hirsch, founder and president of Syapse.

FDA’s regulatory science activities are working to advance the field of precision oncology, in part by using predictive analyses to identify patients that may be good candidates for certain therapies, according to Sean Khozin, MD, MPH, senior medical officer at the FDA.

The Lancet study shows addition of bortezomib significantly improves survival in treatment-naïve patients with multiple myeloma.

Using angiogenesis inhibitors in patients with glioblastoma that is highly vascularized could yield much improved outcomes, the analysis found.

This week, the top managed care stories included CMS announcing more mandatory bundled payment models and a new track in the Medicare Shared Savings Program, the FDA approving a new use for Dexcom's continuous glucose monitor, and a greater emphasis on lifestyle management in the American Diabetes Association's care standards.

The kind of data oncologists need to move towards value-based care isn’t easily accessible in patient electronic health records, but new platforms like Cancer Outcomes Tracking and Analysis (COTA) are trying to make it easier, said Stuart Goldberg, MD, chief medical officer, COTA, John Theurer Cancer Center.

A new study has found that women chose not to go ahead with contralateral prophylactic mastectomy (CPM) if their surgeon recommended against it.

Adolescents who have “adult-type” cancers should be enrolled in relevant clinical trials to improve access for this population of patients, experts from the FDA write in a recently published perspective.

Researchers at the Moffitt Cancer Center have developed a genomics model called genomic-adjusted radiation dose that can guide the radiation dose to match a tumor’s radiosensitivity.

Along with the peer-review research, journal articles, and news coverage, The American Journal of Managed Careâ„¢ (AJMCâ„¢) has a robust multimedia component that brings together stakeholders from across the healthcare industry to discuss important topics in the world of managed care and delve deeper into topics.

The 21st Century Cures Act mandates the creation of "one or more" intercenter institutes at the FDA. But is such a massive reorganization feasible within the FDA?

The FDA has provided accelerated approval for rupacarib along with the first next-generation sequencing—based companion diagnostic test, for the treatment of women with advanced ovarian cancer.

Here's a look at some of the most popular articles published in Evidence-Based Oncologyâ„¢ in 2016.

At the Payer Exchange Summit V, in Tyson’s Corner, Virginia, oncologists and payers came together to discuss the role of collaboration and data sharing for the successful implementation of the Oncology Care Model (OCM).

The new era of data informatics tools can help providers and payers understand the tiers of risk that determine the economics of care delivery, which is crucial to value-based cancer treatment, according to Joseph Alvarnas, MD, of the City of Hope and editor-in-chief of Evidence-Based Oncology